Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography.

Patrick KS, Rodriguez W.

Drug Metab Dispos. 2019 Jul;47(7):764-767. doi: 10.1124/dmd.119.087189. Epub 2019 Apr 26.

PMID:
31028056
2.

Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.

Patrick KS, Radke JL, Raymond JR, Koller L, Nguyen LV, Rodriguez W, Straughn AB.

Pharmacotherapy. 2019 Jun;39(6):677-688. doi: 10.1002/phar.2190. Epub 2018 Nov 23. Review.

PMID:
30351459
3.

The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder.

Markowitz JS, Patrick KS.

J Child Adolesc Psychopharmacol. 2017 Oct;27(8):678-689. doi: 10.1089/cap.2017.0071. Epub 2017 Sep 14. Review.

PMID:
28910145
4.

Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.

Zhu HJ, Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Shi J, Johnson HJ, Knight JM, Smith AT, Malcolm RJ, Markowitz JS.

J Clin Psychopharmacol. 2017 Aug;37(4):419-428. doi: 10.1097/JCP.0000000000000721.

5.

Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate.

Patrick KS, Straughn AB.

Drug Metab Dispos. 2016 Mar;44(3):418-21. doi: 10.1124/dmd.115.067975. Epub 2016 Jan 4.

6.

Comparative Ethanol-Induced Potentiation of Stimulatory Responses to Dexmethylphenidate Versus Methylphenidate.

Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Malcolm R.

J Clin Psychopharmacol. 2015 Aug;35(4):464-7. doi: 10.1097/JCP.0000000000000348.

7.

Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker.

Patrick KS, Corbin TR, Murphy CE.

J Pharm Sci. 2014 Dec;103(12):3834-3842. doi: 10.1002/jps.24202. Epub 2014 Oct 9. Review.

8.

Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability.

Markowitz JS, Zhu HJ, Patrick KS.

J Child Adolesc Psychopharmacol. 2013 Dec;23(10):648-54. doi: 10.1089/cap.2013.0074. Epub 2013 Nov 21.

9.

An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.

Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Patrick KS, Markowitz JS.

Drug Metab Dispos. 2013 Sep;41(9):1679-85. doi: 10.1124/dmd.113.052423. Epub 2013 Jul 8.

10.

Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans.

Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Bell GH, Anderson ER, Malcolm RJ.

Drug Metab Dispos. 2013 Jan;41(1):197-205. doi: 10.1124/dmd.112.048595. Epub 2012 Oct 25.

11.

Interactive effects of methylphenidate and alcohol on discrimination, conditioned place preference and motor coordination in C57BL/6J mice.

Griffin WC 3rd, McGovern RW, Bell GH, Randall PK, Middaugh LD, Patrick KS.

Psychopharmacology (Berl). 2013 Feb;225(3):613-25. doi: 10.1007/s00213-012-2849-z. Epub 2012 Sep 7.

12.

Oral and transdermal DL-methylphenidate-ethanol interactions in C57BL/6J mice: potentiation of locomotor activity with oral delivery.

Bell GH, Griffin WC 3rd, Patrick KS.

Pharmacol Biochem Behav. 2011 Dec;100(2):264-70. doi: 10.1016/j.pbb.2011.08.026. Epub 2011 Sep 8.

13.

Enantiospecific determination of DL-methylphenidate and DL-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions.

Zhu HJ, Patrick KS, Markowitz JS.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Apr 1;879(11-12):783-8. doi: 10.1016/j.jchromb.2011.02.033. Epub 2011 Feb 25.

14.

Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations.

Bell GH, Novak AJ, Griffin WC 3rd, Patrick KS.

J Pharm Sci. 2011 Jul;100(7):2966-78. doi: 10.1002/jps.22476. Epub 2011 Jan 14.

15.

The discriminative stimulus properties of methylphenidate in C57BL/6J mice.

McGovern RW, Middaugh LD, Patrick KS, Griffin WC 3rd.

Behav Pharmacol. 2011 Feb;22(1):14-22. doi: 10.1097/FBP.0b013e3283423d92.

16.

The interactive effects of methylphenidate and ethanol on ethanol consumption and locomotor activity in mice.

Griffin WC 3rd, Novak AJ, Middaugh LD, Patrick KS.

Pharmacol Biochem Behav. 2010 May;95(3):267-72. doi: 10.1016/j.pbb.2010.01.009. Epub 2010 Feb 1.

17.

Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Patrick KS, Straughn AB, Perkins JS, González MA.

Hum Psychopharmacol. 2009 Jan;24(1):1-17. doi: 10.1002/hup.992. Review.

18.

Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?

Markowitz JS, Patrick KS.

J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S54-61. doi: 10.1097/JCP.0b013e3181733560. Review.

PMID:
18480678
19.

Given the multifaceted nature of ADHD, namely its physiologic, cognitive, psychological, and behavioral manifestations, multimodal approaches to treatment are advocated. Introduction.

Markowitz JS, Patrick KS.

J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S37-8. doi: 10.1097/JCP.0b013e3181733143. No abstract available.

PMID:
18480675
20.

Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.

Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, Langaee TY, Markowitz JS.

Am J Hum Genet. 2008 Jun;82(6):1241-8. doi: 10.1016/j.ajhg.2008.04.015. Epub 2008 May 15.

21.

Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping.

LeVasseur NL, Zhu HJ, Markowitz JS, DeVane CL, Patrick KS.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Feb 1;862(1-2):140-9. Epub 2007 Dec 4.

22.

A novel HPLC fluorescence method for the quantification of methylphenidate in human plasma.

Zhu HJ, Wang JS, Patrick KS, Donovan JL, DeVane CL, Markowitz JS.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 15;858(1-2):91-5. Epub 2007 Aug 19.

23.

Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice.

Boger HA, Middaugh LD, Patrick KS, Ramamoorthy S, Denehy ED, Zhu H, Pacchioni AM, Granholm AC, McGinty JF.

J Neurosci. 2007 Aug 15;27(33):8816-25.

24.

Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.

Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, Markowitz JS.

Clin Pharmacol Ther. 2007 Mar;81(3):346-53.

25.

Role of Ca2+-independent phospholipase A2gamma in Ca2+-induced mitochondrial permeability transition.

Kinsey GR, McHowat J, Patrick KS, Schnellmann RG.

J Pharmacol Exp Ther. 2007 May;321(2):707-15. Epub 2007 Feb 20.

PMID:
17312185
26.
27.

A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study.

Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R.

J Child Adolesc Psychopharmacol. 2006 Dec;16(6):687-98.

PMID:
17201613
28.

The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine.

Zhu HJ, Wang JS, DeVane CL, Williard RL, Donovan JL, Middaugh LD, Gibson BB, Patrick KS, Markowitz JS.

Drug Metab Dispos. 2006 Jul;34(7):1116-21. Epub 2006 Apr 18.

PMID:
16621932
29.

Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis.

Njoku CJ, Patrick KS, Ruiz P Jr, Oates JC.

J Investig Med. 2005 Nov;53(7):347-52. doi: 10.2310/6650.2005.53705.

PMID:
16297360
30.

New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.

Patrick KS, González MA, Straughn AB, Markowitz JS.

Expert Opin Drug Deliv. 2005 Jan;2(1):121-43. Review. Erratum in: Expert Opin Drug Deliv. 2005 Mar;2(2):417.

PMID:
16296740
31.

Oral administration of a decaffeinated green tea (Camellia sinensis) extract did not alter urinary 8-epi-prostaglandin F(2 alpha), a biomarker for in-vivo lipid peroxidation.

Donovan JL, DeVane CL, Chavin KD, Oates JC, Njoku C, Patrick KS, Fiorini RN, Markowitz JS.

J Pharm Pharmacol. 2005 Oct;57(10):1365-9.

PMID:
16259767
32.

Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol.

Patrick KS, Williard RL, VanWert AL, Dowd JJ, Oatis JE Jr, Middaugh LD.

J Med Chem. 2005 Apr 21;48(8):2876-81.

PMID:
15828826
33.

CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis.

Gupta RP, He YA, Patrick KS, Halpert JR, Bell NH.

J Clin Endocrinol Metab. 2005 Feb;90(2):1210-9. Epub 2004 Nov 16.

PMID:
15546903
34.

CYP3A4 is a human microsomal vitamin D 25-hydroxylase.

Gupta RP, Hollis BW, Patel SB, Patrick KS, Bell NH.

J Bone Miner Res. 2004 Apr;19(4):680-8. Epub 2003 Dec 22.

35.

Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.

Markowitz JS, Straughn AB, Patrick KS.

Pharmacotherapy. 2003 Oct;23(10):1281-99. Review.

PMID:
14594346
36.

Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.

Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, Wang Y, Muniz R.

Clin Pharmacokinet. 2003;42(4):393-401.

PMID:
12648029
37.

Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Markowitz JS, Patrick KS.

Clin Pharmacokinet. 2001;40(10):753-72. Review.

PMID:
11707061
38.

Methylphenidate ER tablet lodging in esophagus.

Wagner MW, Markowitz JS, Patrick KS.

J Am Acad Child Adolesc Psychiatry. 2001 Nov;40(11):1244-5. No abstract available.

PMID:
11699796
39.

Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability.

Meyer MC, Straughn AB, Jarvi EJ, Patrick KS, Pelsor FR, Williams RL, Patnaik R, Chen ML, Shah VP.

Pharm Res. 2000 Apr;17(4):381-4.

PMID:
10870979
40.

Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol.

Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, Patrick KS.

Drug Metab Dispos. 2000 Jun;28(6):620-4.

PMID:
10820132
41.

Stability of meperidine in an implantable infusion pump using capillary gas chromatography-mass spectrometry and a deuterated internal standard.

Harvey SC, Toussaint CP, Coe SE, Watson EE, O'Neil MG, Patrick KS.

J Pharm Biomed Anal. 1999 Nov;21(3):577-83.

PMID:
10701424
42.

Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion.

Markowitz JS, Logan BK, Diamond F, Patrick KS.

J Clin Psychopharmacol. 1999 Aug;19(4):362-6.

PMID:
10440465
43.

Venlafaxine-tramadol similarities.

Markowitz JS, Patrick KS.

Med Hypotheses. 1998 Aug;51(2):167-8.

PMID:
9881825
44.

Potential for overestimation of clozapine concentrations.

Patrick KS, Markowitz JS.

J Anal Toxicol. 1997 Jan-Feb;21(1):73-5. No abstract available.

PMID:
9013297
45.

A murine model of prenatal cocaine exposure: effects on the mother and the fetus.

Middaugh LD, Boggan WO, Bingel SA, Patrick KS, Xu W.

Pharmacol Biochem Behav. 1996 Dec;55(4):565-74.

PMID:
8981587
46.

Cocaine concentrations in fetal C57BL/6 mouse brain relative to maternal brain and plasma.

Miller SR, Middaugh LD, Boggan WO, Patrick KS.

Neurotoxicol Teratol. 1996 Nov-Dec;18(6):645-9. Erratum in: Neurotoxicol Teratol 1997 Jan-Feb;19(1):75.

PMID:
8947941
47.
48.

Acute gestational cocaine exposure alone or in combination with low-dose ethanol does not influence prenatal mortality or fetal weight in mice.

Salo AL, Randall CL, Becker HC, Patrick KS.

Neurotoxicol Teratol. 1995 Sep-Oct;17(5):577-81.

PMID:
8552004
49.

Thermal degradation of clozapine-N-oxide to clozapine during gas chromatographic analysis.

Markowitz JS, Patrick KS.

J Chromatogr B Biomed Appl. 1995 Jun 9;668(1):171-4.

PMID:
7550974
50.

Gas chromatographic-mass spectrometric determination of urinary 1-aminocyclopropanecarboxylic acid in mice using a deuterated internal standard.

Howell SE, Miller SR, McCallister JD, Cherkofsky SC, Patrick KS.

J Chromatogr B Biomed Appl. 1995 Jan 6;663(1):148-52.

PMID:
7704202

Supplemental Content

Loading ...
Support Center